ALK - THE ALLERGY COMPANY

Pioneering allergy research

Understanding allergy

ALK has an unrivalled understanding of allergens and how they affect the human body, as well as the link between allergy and respiratory diseases such as asthma.

understanding_allergy

Watch the presentation

News

See all

Post date
11/13/2018

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Read more
Post date
11/09/2018

Nine-month interim report (Q3) 2018

Read more
Post date
11/05/2018

Correction: Release date of nine-month interim report (Q3) 2018 and audio cast

Read more
Post date
11/05/2018

Release date of nine-month interim report (Q3) 2018 and audio cast

Read more
Post date
10/17/2018

UK authority extends use of specific batches of Jext® as adrenaline pen shortage continues

Read more
Post date
08/22/2018

ALK submits registration application for tree SLIT-tablet in Europe

Read more
Post date
08/15/2018

Six-month interim report (Q2) 2018

Read more
Post date
08/09/2018

Release date of six-month interim report (Q2) 2018 and audio cast

Read more
Post date
05/04/2018

Three-month interim report (Q1) 2018

Read more

ALK launches growth strategy

Transformational strategy to redefine ALK's position in the global allergy market and stimulate a new era of growth for the company.

Growth strategy: Establish and succeed in North America

North America is the world's largest allergy market, with over 50 million allergy sufferers, and it offers ALK the greatest medium-term growth potential. For example, there are around 10 million AIT-eligible allergy sufferers in the USA alone, just one-third of whom actually receive AIT today.

Growth strategy: Complete the tablet portfolio for all relevant ages

ALK is committed to offering a full portfolio of tablets for all relevant ages, covering the five most common global respiratory allergies.

Growth strategy: Patient engagement systems and adjacent business

ALK will establish a new commercial consumer care division to drive digital patient engagement with the ultimate aim of creating new value from ALK's expanded allergy presence.

ALK in brief

ALK at a glance

ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy.

Pioneering allergy research

Under­standing allergy

understanding_allergy

News

ALK in brief

Understanding allergy